Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Coherus Oncology (NASDAQ:CHRS) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03), FiscalAI reports.

Coherus Oncology Price Performance

Shares of CHRS traded up $0.11 during mid-day trading on Monday, reaching $1.93. The company had a trading volume of 2,183,524 shares, compared to its average volume of 2,544,500. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.24 and a quick ratio of 1.23. The company has a market capitalization of $288.48 million, a P/E ratio of 1.45 and a beta of 1.05. Coherus Oncology has a twelve month low of $0.71 and a twelve month high of $2.62. The company’s 50-day moving average is $1.77 and its 200-day moving average is $1.54.

Institutional Trading of Coherus Oncology

Large investors have recently bought and sold shares of the stock. Jefferies Financial Group Inc. lifted its holdings in shares of Coherus Oncology by 2.5% during the third quarter. Jefferies Financial Group Inc. now owns 325,625 shares of the biotechnology company’s stock valued at $534,000 after acquiring an additional 8,000 shares during the period. Corient Private Wealth LLC grew its holdings in shares of Coherus Oncology by 20.0% in the 2nd quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 10,000 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Coherus Oncology by 108.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 13,832 shares in the last quarter. Quarry LP bought a new position in Coherus Oncology during the 3rd quarter valued at about $26,000. Finally, Ieq Capital LLC lifted its holdings in Coherus Oncology by 24.9% during the 4th quarter. Ieq Capital LLC now owns 79,128 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 15,751 shares during the last quarter. 72.82% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Oppenheimer began coverage on shares of Coherus Oncology in a research note on Thursday, January 22nd. They issued an “outperform” rating and a $10.00 price objective for the company. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Coherus Oncology has an average rating of “Hold” and a consensus price target of $5.51.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.